Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15696203.
- Also identified by PMC identifier 545205.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Gefitinib and erlotinib are two new treatments for advanced lung cancer. Gene mutations in the cancer may help predict which patients will respond to these treatments
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- DNA Mutational Analysis
- Lung Neoplasms